Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.32 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27170378 | 1.00 | TMEM97 (0.32) | TMEM97SIGMAR1HCRTR2 | |
| SCHEMBL15989518 | 1.00 | TMEM97 (0.32) | TMEM97SIGMAR1HCRTR2 | |
| SCHEMBL13053762 | 1.00 | TMEM97 (0.32) | TMEM97SIGMAR1HCRTR2 | |
| SCHEMBL12712729 | 0.84 | HCRTR1 (0.35) | HCRTR2 | |
| SCHEMBL15989519 | 0.83 | HCRTR2 (0.36) | HCRTR2 | |
| SCHEMBL13053777 | 0.81 | HCRTR1 (0.31) | HCRTR2 | |
| SCHEMBL13970486 | 0.81 | HCRTR1 (0.31) | HCRTR2 | |
| SCHEMBL13053732 | 0.80 | TMEM97 (0.32) | TMEM97SIGMAR1 | |
| SCHEMBL13053787 | 0.79 | CA1 (0.36) | HCRTR2 | |
| SCHEMBL12712836 | 0.79 | ELANE (0.34) | TMEM97SIGMAR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250325570-A1 | DOSE AND REGIMEN FOR A HETEROCYCLIC PHOSPHINIC COMPOUND | PHOST'IN THERAPEUTICS (FR) | 2025-10-23 | — | — | US | disclosed |
| US-20240082271-A1 | Methods of Treatment of Fibrotic Diseases | RD NEPHROLOGIE (FR) | 2024-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250325570-A1 | DOSE AND REGIMEN FOR A HETEROCYCLIC PHOSPHINIC COMPOUND | PHPT1, CDC25A, CDC25C | TMEM97 4716/4885SIGMAR1 4547/4885HCRTR2 2717/4885 |
| US-20240082271-A1 | Methods of Treatment of Fibrotic Diseases | MMP1, COL2A1, COL1A1 | TMEM97 3393/4885SIGMAR1 3507/4885HCRTR2 1786/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.